Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a trial of KDS2010 in mild Alzheimer's disease and MCI due to Alzheimer's disease
KCT0010589Phase 2Recruiting
- Sponsor
- NeuroBiogen
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tisolagiline in Alzheimer's disease (AD), mild cognitive impairment due to Alzheimer's disease, sponsored by NeuroBiogen. Started Aug 2025; status: recruiting.
02
Drugs
tisolagiline
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on KCT0010589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010589.